-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Harbour Pharmaceuticals (stock code: 02142.
HK) today announced that its wholly-owned subsidiary, Nona Biologics, and ModernaTX, a leading global mRNA and vaccine research and development company, ModernaTX,
NASDAQ: MRNA) signed a licensing and partnership agreement to leverage the company's proprietary fully human heavy-chain antibody platform, HCAb, to research and develop gene immunotherapies
.
HK) Nona BioModerna (ModernaTX, NASDAQ: MRNA) fully human heavy-chain antibody platform HCAb gene immunotherapy
Under the agreement, Moderna will receive a set of exclusive, sublicensable licenses for multiple target sequences developed by the HCAb platform for gene therapy research and development, with overall responsibility for all aspects
related to its development, manufacturing, regulation and commercialization.
Nona Biologics will receive a one-time upfront payment of $6 million, milestone payments of up to approximately $500 million and related tiered royalties
.
In addition, Moderna will have the option to receive an exclusive sublicensable license for additional target sequences, and Nona Biologics will receive the corresponding upfront payment, milestone payment and tiered royalties
.
Dr.
Jinsong Wang, Founder, Chairman and CEO of Harbour Pharmaceutical, said: "We are delighted to partner
with Moderna, an innovation pioneer in the mRNA space.
The signing of this agreement is a major milestone in the company's business development and another proof
of the innovation of the company's own antibody technology platform.
With our strong platform R&D capabilities, we have achieved outstanding commercial results on a global scale, and will further open up our access to share our technology, know-how and experience with innovators around the world to empower global biotherapeutics innovation
.
"Nona Biologics (a wholly-owned subsidiary of Harbour Biopharma) is an international innovative biotechnology company committed to providing multinational pharmaceutical companies, biopharmaceutical companies, and scientific research and academic institutions with target validation and diversified drug molecules from discovery to preclinical development"I
to ITM（Idea to
IND) "Full service
.
Using an integrated and innovative technology platform and an experienced team of scientists, the company provides one-stop antibody discovery solutions
covering antigen preparation, animal immunity, single B cell screening, antibody development and engineering, druggability evaluation and pharmacological evaluation.
.
Dr.
Wang Jinsong, Founder, Chairman and CEO of Harbour Biopharma, said: Nona Biologics (a wholly-owned subsidiary of Harbour Biopharma
On April 7, Harbour Pharmaceuticals and AstraZeneca reached a global licensing agreement
for the development and commercialization of CLDN18.
2xCD3 bispecific antibody (HBM7022).
AstraZeneca will receive an exclusive worldwide license for the research, development, registration, manufacturing and commercialization of HBM7022 and will be responsible for all costs
associated with the further preclinical development and commercialization of HBM7022.
Harbour BioMed will receive an upfront payment of $25 million and milestone payments of up to $325 million, as well as royalties
based on future HBM7022 sales.
On May 30, Harbour Biopharma announced that it has partnered with LegoChem
Biosciences and IngenBiologics have entered into a collaborative project on antibody drug conjugates (ADCs) as part
of Harbour Pharma's ADC development and collaboration strategy.
(Signed two ADC cooperation agreements with Platinum Pharmaceutical)
On October 10, Harbour Biopharma announced that it has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group Enbipu Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of CSPC Pharmaceutical Group, pursuant to which Ambipu Pharmaceutical has obtained an exclusive license from Shanghai Harbour Pharmaceutical to develop, manufacture and commercialize bartolimab (HBM9161)
in Greater China, including Chinese mainland, Hong Kong, Macau and Taiwan.
(Harbour Pharmaceuticals sold bartolimab for more than 1 billion yuan and terminated the phase III clinical trial of teraercept)
, Ltd.
Bartolimab (HBM9161)
On the same day, Harbour BioMed announced that it had decided to close its Phase III trial of tenacercept (HBM9036) in China and not enroll new subjects
in accordance with the recommendations of the Independent Data Monitoring Committee (IDMC).
In 2017, Harbour Biomed introduced the Greater China interests
of bartolimab (HBM9161) and tenaercept (HBM9036) from HanAll for US$81 million.
.
